Cor Vasa 2022, 64(Suppl. 1):7-28 | DOI: 10.33678/cor.2021.140

2022 Summary of recommendations for long-term secondary prevention after myocardial infarction

Petr Ošťádala, Miloš Táborskýb, Aleš Linhartc, Michal Vrablíkd, Richard Češkad, Renata Cífkovác, e, Eva Králíkováf, g, Věra Adámkováh, Martin Práznýd, Zorjan Jojkoch
a Kardiovaskulární centrum, Nemocnice Na Homolce, Praha
b I. interní klinika - kardiologická, Lékařská fakulta Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc, Olomouc
c II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha
d III. interní klinika - klinika endokrinologie a metabolismu, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha
e Centrum kardiovaskulární prevence, 1. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice, Praha
f Centrum pro závislé na tabáku, III. interní klinika - klinika endokrinologie a metabolismu, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha
g Ústav hygieny a epidemiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha
h Pracoviště preventivní kardiologie, Institut klinické a experimentální medicíny, Praha
ch Kardiomed s.r.o., Praha

Keywords: antithrombotic agents, atrial fibrillation, diabetes mellitus, diet, hypertension, lipid-lowering drugs, myocardial infarction, physical activity, secondary prevention, smoking

Received: December 13, 2021; Accepted: December 15, 2021; Published: February 2, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ošťádal P, Táborský M, Linhart A, Vrablík M, Češka R, Cífková R, et al.. 2022 Summary of recommendations for long-term secondary prevention after myocardial infarction. Cor Vasa. 2022;64(Suppl. 1):7-28. doi: 10.33678/cor.2021.140.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-177. Go to original source... Go to PubMed...
    2. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213-260. Go to original source... Go to PubMed...
    3. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165. Go to original source... Go to PubMed...
    4. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289-1367. Go to original source... Go to PubMed...
    5. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-477. Go to original source... Go to PubMed...
    6. Moťovská Z, Kala P, Hutyra M, Hromádka M. Doporučení ESC pro léčbu akutních koronárních syndromů u pacientů prezentujících se bez přetrvávající elevace úseku ST, 2020.Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa 2021;63:197-234. Go to original source...
    7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-188. Go to original source... Go to PubMed...
    8. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-1722. Go to original source... Go to PubMed...
    9. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018;379:2097-2107. Go to original source... Go to PubMed...
    10. Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016;388:2142-2152. Go to original source... Go to PubMed...
    11. Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 2017;389:2226-2237. Go to original source... Go to PubMed...
    12. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018;36:1953-2041. Go to original source... Go to PubMed...
    13. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta- -analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. Go to original source... Go to PubMed...
    14. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726. Go to original source... Go to PubMed...
    15. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio- -Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498. Go to original source... Go to PubMed...
    16. Fiala M, Haman L, Čihák R. Doporučení ESC pro diagnostiku a léčbu fibrilace síní, 2020. Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa 2021;63:135-161. Go to original source...
    17. Škrha J, Pelikánová T, Kvapil M. Doporučený postup péče o diabetes mellitus 2. typu. http://www.diab.cz/dokumenty/standard_lecba_dm_typ_II.pdf.
    18. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772. Go to original source... Go to PubMed...
    19. Oellgaard J, Gæde P, Rossing P, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018;61:1724-1733. Go to original source... Go to PubMed...
    20. Schernthaner G. Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE- -SUGAR. Wien Med Wochenschr 2010;160:8-19. Go to original source... Go to PubMed...
    21. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669-2701. Go to original source... Go to PubMed...
    22. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117-2128. Go to original source... Go to PubMed...
    23. Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular
    24. outcome results (LEADER) trial. Am Heart J 2013;166:823.e5-830.e5. Go to original source... Go to PubMed...
    25. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780. Go to original source... Go to PubMed...
    26. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta- -analysis of cardiovascular outcome trials. Lancet 2019;393:31-39. Go to original source... Go to PubMed...
    27. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381:1995-2008. Go to original source... Go to PubMed...
    28. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446. Go to original source... Go to PubMed...
    29. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020;383:1413-1424. Go to original source... Go to PubMed...
    30. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021;385:1451-1461. Go to original source... Go to PubMed...
    31. Fiore MC, Jaén CR, Baker TB. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. US Department of Health and Human Services: Rockville (MD) 2008. Update 2015.
    32. Králíková E, Češka R, Pánková A, et al. Doporučení pro léčbu závislosti na tabáku. Vnitř Lék 2015;61(5, Suppl 1):1S4-1S15.
    33. WHO, Healthy Diet. https://www.who.int/news-room/fact-sheets/detail/healthy-diet, 2020.
    34. Freeman AM, Morris PB, Barnard N, et al. Trending Cardiovascular Nutrition Controversies. J Am Coll Cardiol 2017;69:1172-1187. Go to original source... Go to PubMed...
    35. Janský P, Rosolová H, Vrablík M. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2017;59:e389-e415. Go to original source...
    36. Ošťádal P, Táborský M, Linhart A, et al. Stručný souhrn doporučení pro dlouhodobou péči o nemocné po infarktu myokardu. Cor Vasa 2019;61:471-480. Go to original source...
    37. Dlouhý P, et al. Zdravá třináctka - stručná výživová doporučení pro obyvatelstvo. Společnost pro výživu (vyzivaspol.cz), 2021.
    38. Briggs MA, Petersen KS, Kris-Etherton PM. Saturated Fatty Acids and Cardiovascular Disease: Replacements for Saturated Fat to Reduce Cardiovascular Risk. Healthcare (Basel) 2017; 5:29. Go to original source... Go to PubMed...
    39. Yu E, Malik VS, Hu FB. Cardiovascular Disease Prevention by Diet Modification: JACC Health Promotion Series. J Am Coll Cardiol 2018;72:914-926. Go to original source... Go to PubMed...
    40. Eilat-Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients 2013;5:3646-3683. Go to original source... Go to PubMed...
    41. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts 2015;8:402-424. Go to original source... Go to PubMed...
    42. Bowen KJ, Sullivan VK, Kris-Etherton PM, Petersen KS. Nutrition and Cardiovascular Disease-an Update. Curr Atheroscler Rep 2018;20:8. Go to original source... Go to PubMed...
    43. Elagizi A, Lavie CJ, Marshall K, et al. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review. Prog Cardiovasc Dis 2018;61:76-85. Go to original source... Go to PubMed...
    44. Tuncay C, Ergoren MC. A systematic review of precision nutrition and Mediterranean Diet: A personalized nutrition approaches for prevention and management of obesity related disorders. Clin Nutr ESPEN 2020;38:61-64. Go to original source... Go to PubMed...
    45. Kunimura A, Ishii H, Uetani T, et al. Impact of nutritional assessment and body mass index on cardiovascular outcomes in patients with stable coronary artery disease. Int J Cardiol 2017;230:653-658. Go to original source... Go to PubMed...
    46. Wada H, Dohi T, Miyauchi K, et al. Relationship between the prognostic nutritional index and long-term clinical outcomes in patients with stable coronary artery disease. J Cardiol 2018;72:55-161. Go to original source... Go to PubMed...
    47. Petersen KS, Flock MR, Richter CK, et al. Healthy Dietary Patterns for Preventing Cardiometabolic Disease: The Role of Plant-Based Foods and Animal Products. Curr Dev Nutr 2017;1:cdn.117.001289. Go to original source... Go to PubMed...
    48. Stránský P. Vliv rostlinných a živočišných tuků na kardiovaskulární onemocnění. In: Adámková V, Zimmelová P (eds.). Sborník II. ročníku mezinárodní konference Výživa - nedílná součást léčby závažných chorob. Jihočeská univerzita v Českých Budějovicích, Zdravotně sociální fakulta a Centrum prevence civilizačních chorob, 2006.
    49. Úřední věstník Evropské unie: Nařízení Evropského parlamentu a Rady (EU) č. 1169/2011. https://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:304:0018:0063:CS:PDF, 2011.
    50. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325:1436-1442. Go to original source... Go to PubMed...
    51. Weinberg RL, Brook RD, Rubenfire M, et al. Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids: JACC Focus Seminar. J Am Coll Cardiol 2021;77:593-608. Go to original source... Go to PubMed...
    52. Anderson L, Oldridge N, Thompson DR, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. J Am Coll Cardiol 2016;67:1-12. Go to original source... Go to PubMed...
    53. Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies - The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016;23:1914-1939. Go to original source... Go to PubMed...
    54. Xia TL, Huang FY, Peng Y, et al. Efficacy of Different Types of Exercise-Based Cardiac Rehabilitation on Coronary Heart Disease: a Network Meta-analysis. J Gen Intern Med 2018;33201-2209. Go to original source... Go to PubMed...
    55. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:17-96. Go to original source... Go to PubMed...
    56. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 2013;128:873-934. Go to original source... Go to PubMed...
    57. Piepoli MF, Corrà U, Benzer W, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010;17:1-17. Go to original source... Go to PubMed...
    58. Piepoli MF, Corrà U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014;21:664-681. Go to original source... Go to PubMed...
    59. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016;23:NP1-NP96. Go to PubMed...
    60. Borjesson M, Dellborg M, Niebauer J, et al. Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019;40:13-18. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes